Live
- All you need to know about PAN 2.0
- Akasa Air redefines travel experience with industry-first offerings
- MP: Residents stage protests against liquor shop in Indore
- Telugu Actor Shri Tej Booked for Alleged Cheating and False Promise of Marriage in Live-in Relationship
- Toyota Kirloskar Motor Celebrates 1 Lakh Urban Cruiser Hyryder on Indian Road
- MLS: New York City FC part ways with head coach Nick Cushing
- Delhi CM says Centre cutting AAP voters’ names from rolls, BJP hits back
- Hyderabad Metro Rail Phase-II Works to Begin in Old City in January 2025
- Odisha: 668 persons killed in human-elephant conflicts in last three years
- DEFENDER JOURNEYS: TO EMBARK ON ITS THIRD EDITION FROM NOVEMBER 2024
Major advances seen in 'non-small cell lung cancer' treatment
Highlights
Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment.
Washington, D.C.: Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment.Now, a new study in mice has shown that cancers with Kirsten rat sarcoma viral oncogene homolog (KRAS)-related gene mutations might benefit from a triple therapy with two experimental drugs plus radiation therapy.
According to professor of Radiation Oncology at Thomas Jefferson University Bo Lu, although further research in human subjects is needed to confirm the finding, the study suggests that there is a possibility to identify non-small cell lung cancer patients who are likely to benefit most from this combination of therapies.
In order to help make these resistant KRAS mutants more susceptible to therapy, the researchers combined the KRAS-targeting drug with another drug that would undo the effects of the p16 mutation.
Currently, neither of two drugs that target KRAS and proteins in the p16 pathway has been approved for use in lung cancer but it is hopeful that this research will help identify the patients who could potentially benefit from a triple-therapy treatment.
The study is published in the Journal Clinical Cancer Research.
Next Story
ADVERTISEMENT
